Glendon E. French III - Feb 17, 2022 Form 4 Insider Report for Pulmonx Corp (LUNG)

Role
President and CEO, Director
Signature
/s/ Lauren Cristina, Attorney-in-Fact for Glendon E. French
Stock symbol
LUNG
Transactions as of
Feb 17, 2022
Transactions value $
-$676,635
Form type
4
Date filed
2/22/2022, 04:45 PM
Previous filing
Jan 24, 2022
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Sale -$340K -12.5K -1.15% $27.22 1.08M Feb 17, 2022 Direct F1, F2
transaction LUNG Common Stock Sale -$230K -8.56K -0.8% $26.81 1.07M Feb 18, 2022 Direct F1, F3
transaction LUNG Common Stock Sale -$107K -3.94K -0.37% $27.13 1.06M Feb 18, 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $27.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.